InMed Pharmaceuticals reported its first quarter fiscal 2027 financial results and is advancing its proposed merger with Mentari Therapeutics, which is expected to close in Q4 2026. The company will also hold an annual general and special meeting on November 4, 2026, to secure shareholder approval for the transaction.